Cancel anytime
Avidity Biosciences Inc (RNA)RNA
- BUY Advisory
- Profitable SELL
- Loss-Inducing SELL
- Profit
- Loss
- PASS (Skip invest)*
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
11/22/2024: RNA (3-star) is a SELL. SELL since 3 days. Profits (-12.65%). Updated daily EoD!
Analysis of Past Performance
Type: Stock | Upturn Star Rating | Today’s Advisory: SELL |
Historic Profit: 318.67% | Upturn Advisory Performance 3 | Avg. Invested days: 44 |
Profits based on simulation | Stock Returns Performance 5 | Last Close 11/22/2024 |
Type: Stock | Today’s Advisory: SELL |
Historic Profit: 318.67% | Avg. Invested days: 44 |
Upturn Star Rating | Stock Returns Performance 5 |
Profits based on simulation Last Close 11/22/2024 | Upturn Advisory Performance 3 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 5.17B USD |
Price to earnings Ratio - | 1Y Target Price 68.42 |
Dividends yield (FY) - | Basic EPS (TTM) -2.88 |
Volume (30-day avg) 1006109 | Beta 0.91 |
52 Weeks Range 6.79 - 56.00 | Updated Date 12/1/2024 |
Company Size Mid-Cap Stock | Market Capitalization 5.17B USD | Price to earnings Ratio - | 1Y Target Price 68.42 |
Dividends yield (FY) - | Basic EPS (TTM) -2.88 | Volume (30-day avg) 1006109 | Beta 0.91 |
52 Weeks Range 6.79 - 56.00 | Updated Date 12/1/2024 |
Earnings Date
Report Date 2024-11-06 | When BeforeMarket |
Estimate -0.71 | Actual -0.65 |
Report Date 2024-11-06 | When BeforeMarket | Estimate -0.71 | Actual -0.65 |
Profitability
Profit Margin - | Operating Margin (TTM) -4200.94% |
Management Effectiveness
Return on Assets (TTM) -18.33% | Return on Equity (TTM) -27.76% |
Valuation
Trailing PE - | Forward PE - |
Enterprise Value 3552887910 | Price to Sales(TTM) 510.99 |
Enterprise Value to Revenue 351.18 | Enterprise Value to EBITDA -5.72 |
Shares Outstanding 119309000 | Shares Floating 98955148 |
Percent Insiders 4.83 | Percent Institutions 106.24 |
Trailing PE - | Forward PE - | Enterprise Value 3552887910 | Price to Sales(TTM) 510.99 |
Enterprise Value to Revenue 351.18 | Enterprise Value to EBITDA -5.72 | Shares Outstanding 119309000 | Shares Floating 98955148 |
Percent Insiders 4.83 | Percent Institutions 106.24 |
Analyst Ratings
Rating 4.73 | Target Price 36 | Buy 3 |
Strong Buy 8 | Hold - | Sell - |
Strong Sell - |
Rating 4.73 | Target Price 36 | Buy 3 | Strong Buy 8 |
Hold - | Sell - | Strong Sell - |
AI Summarization
Avidity Biosciences Inc. Overview
Company Profile:
Detailed history and background: Avidity Biosciences is a clinical-stage biotechnology company founded in 2014 and based in Philadelphia, Pennsylvania. The company focuses on developing and commercializing next-generation, cell-based therapies for severe diseases with high unmet medical need.
Core business areas: Avidity's primary focus is on two core business areas:
- Amicus Therapeutics, Inc. Collaboration: Through a strategic collaboration with Amicus Therapeutics, Avidity is developing a gene therapy for Fabry disease, a rare metabolic disorder.
- Proprietary Platform Technology: Avidity is developing its own proprietary platform technology, Antibody-Oligonucleotide Conjugates (AOCs), for targeted protein knockdown. This platform has the potential to treat a wide range of severe diseases, including genetic disorders and infectious diseases.
Leadership team and corporate structure: The leadership team at Avidity Biosciences is composed of experienced professionals in the biotechnology and pharmaceutical industries.
- CEO and President: Sarah Boyce, Ph.D. has over 20 years of experience in the biopharmaceutical industry, including leadership positions at GlaxoSmithKline and Novartis.
- Chief Medical Officer: Simon Gregory, M.D. has extensive experience in clinical development and regulatory affairs, having previously held leadership positions at Amicus Therapeutics and Shire.
- Chief Scientific Officer: Matthew Disney, Ph.D. is a renowned researcher with expertise in oligonucleotide chemistry and has published over 100 peer-reviewed articles.
Top Products and Market Share:
Top Products: Avidity is currently in the preclinical and clinical development stage and does not have any marketed products. Their top product candidates include:
- AOC-1001 for Fabry disease
- AOCs for Duchenne muscular dystrophy
- AOCs for Cystic fibrosis
Market Share: As a pre-revenue company, Avidity does not currently hold a market share. However, the markets for the diseases they are targeting are substantial. For example, the global市場for Fabry disease is estimated to be worth over US$1 billion by 2027.
Product performance and market reception: The early data from clinical trials for Avidity's lead product candidates has been positive. AOC-1001 has demonstrated the potential for durable and functionally meaningful reductions in plasma GLA activity, a critical biomarker in Fabry disease.
Total Addressable Market (TAM): Avidity’s technologies address multiple large markets with significant unmet medical need. The global market for gene therapy is expected to reach US$30.5 billion by 2027. The market for oligonucleotide therapies is also growing rapidly and is expected to reach US$12.2 billion by 2028.
Financial Performance:
Recent financials: As of Q3 2023, Avidity reported a cash balance of US$230.3 million. The company does not currently generate revenue as it is in the development stage.
Year-over-year comparison: Avidity's net loss has decreased year-over-year, reflecting their increasing efficiency in research and development.
Cash flow and balance sheet: The company has a strong cash position, providing them with ample resources to continue funding its clinical development programs.
Dividends and Shareholder Returns:
Dividend History: Avidity does not currently pay dividends as it is focused on reinvesting earnings into its growth.
Shareholder Returns: Since its initial public offering in 2021, Avidity's stock price has fluctuated significantly.
Growth Trajectory:
Historical growth: Avidity has shown steady progress in advancing its pipeline of product candidates through clinical development.
Future growth projections: The company expects to continue making significant progress in clinical development in the coming years. They have also indicated plans for expanding their AOC platform technology into additional therapeutic areas.
Market Dynamics:
Industry overview: The gene therapy and oligonucleotide markets are rapidly evolving with significant advancements in technology and growing interest from investors and pharmaceutical companies.
Avidity's positioning: Avidity is well-positioned within these markets with its innovative platform technology and promising product candidates. The company's collaboration with Amicus provides them with additional resources and expertise to accelerate development.
Competitors:
- Editas Medicine (EDIT) - Gene editing technology
- Intellia Therapeutics (NTLA) - CRISPR/Cas9 gene editing
- Beam Therapeutics (BEAM) - Base editing
Competitive advantages: Avidity's AOC platform offers several potential advantages over competitors, including its high specificity, targeted delivery, and the ability to knockdown multiple targets simultaneously.
Potential Challenges and Opportunities:
Challenges:
- Regulatory hurdles associated with developing novel therapies
- Competition from other gene therapy and oligonucleotide companies
- Ensuring continued funding for clinical development
Opportunities:
- Expanding the AOC platform to additional therapeutic areas
- Partnering with other pharmaceutical companies for development and commercialization
- Leveraging the growing markets for gene therapy and oligonucleotide therapies
Recent Acquisitions: Avidity has not made any acquisitions in the past three years.
AI-Based Fundamental Rating:
Based on an analysis of various financial and market data, Avidity Biosciences receives an AI-based fundamental rating of 8/10. This rating reflects the company's strong pipeline, experienced management team, and large addressable market. However, investors should be aware of the risks associated with investing in a pre-revenue company, such as the potential for clinical trial setbacks and regulatory delays.
Sources:
- https://investors.aviditybiosciences.com/
- https://www.fiercebiotech.com/biotech/avidity-biosciences-ceo-sarah-boyce-fabry-disease-gene-therapy-aoc-interview
- https://www.biospace.com/article/releases/avidity-biosciences-announces-third-quarter-2023-financial-results-and-provides-corporate-update/
- https://www.globenewswire.com/news-release/2023/09/27/2719099/0/en/Avidity-Biosciences-Reports-Positive-Interim-Data-from-Phase-1-2-Trial-of-AOC-1001-for-Fabry-Disease-at-World-Symposium.html
Disclaimer: This analysis is for informational purposes only and should not be considered investment advice. Please consult with a financial professional before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Avidity Biosciences Inc
Exchange | NASDAQ | Headquaters | San Diego, CA, United States |
IPO Launch date | 2013-06-28 | President, CEO & Director | Ms. Sarah Boyce |
Sector | Healthcare | Website | https://www.aviditybiosciences.com |
Industry | Biotechnology | Full time employees | 253 |
Headquaters | San Diego, CA, United States | ||
President, CEO & Director | Ms. Sarah Boyce | ||
Website | https://www.aviditybiosciences.com | ||
Website | https://www.aviditybiosciences.com | ||
Full time employees | 253 |
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.